Skip to main content
Home
FULL MENU Close Menu
Home
Home

Neil Osterweil

News

Rituximab Reduces Chronic GVHD After Allogeneic Stem Cell Transplant

Author:
Neil Osterweil
Publish date: December 17, 2010

Major Finding: Rituximab prophylaxis reduced the incidence of chronic GVHD following allogeneic stem cell transplant by at least 50%.Data Source:...

  • Read More

News

Bortezomib-Based Regimens Help Older Patients With Multiple Myeloma

Author:
Neil Osterweil
Publish date: December 15, 2010

Major Finding: Very good partial response rates ranged from 39% to 47% after maintenance therapy in a comparison of three bortezomib-containing...

  • Read More

News

Ara-C Prolongs Time to Treatment Failure in Mantle Cell Lymphoma

Author:
Neil Osterweil
Publish date: December 13, 2010

Major Finding: A conditioning regimen of R-CHOP alternating with R-DHAP and high dose cytarabine followed by stem-cell transplant improved time to...

  • Read More

News

BEACOPP Plus ABVD Called 'New Standard' for Hodgkin's Lymphoma

Author:
Neil Osterweil
Publish date: December 9, 2010

Major Finding: Combining two cycles of BEACOPP with two of ABVD significantly improves time to treatment failure (but not overall survival) in...

  • Read More

News

Imatinib Plus Bone Marrow Transplant Boost Survival in Ph+ ALL

Author:
Neil Osterweil
Publish date: December 6, 2010

Major Finding: The 3-year overall survival of Philadelphia chromosome–positive ALL improved from 25%, before imatinib was introduced, to 43% after...

  • Read More

News

Scoring System Predicts Recurrent VTE Risk in Cancer Patients

Author:
Neil Osterweil
Publish date: December 6, 2010

Major Finding: Predictors for risk of recurrent venous thromboembolism (VTE) in cancer patients are lung cancer, female gender, and a prior VTE....

  • Read More

News

Study Shows Rivaroxaban Valid for VTE Prophylaxis

Author:
Neil Osterweil
Publish date: December 6, 2010

Major Finding: Venous thromboembolism recurred in 2.1% of patients randomized to rivaroxaban and in 3.0% of patients randomized to enoxaparin...

  • Read More

News

Study Shows Rivaroxaban Valid for VTE Prophylaxis

Author:
Neil Osterweil
Publish date: December 6, 2010

Major Finding: Venous thromboembolism recurred in 2.1% of patients randomized to rivaroxaban and in 3.0% of patients randomized to enoxaparin...

  • Read More

News

Chondrocyte Implants Give Lasting Benefits

Author:
Neil Osterweil
Publish date: December 1, 2010

  • Read More

News

Can Bundled Cancer-Care Payments Save a Bundle?

Author:
Neil Osterweil
Publish date: November 17, 2010

  • Read More

News

Can Bundled Cancer-Care Payments Save a Bundle?

Author:
Neil Osterweil
Publish date: November 17, 2010

  • Read More

News

Can Bundled Cancer-Care Payments Save a Bundle?

Author:
Neil Osterweil
Publish date: November 17, 2010

  • Read More

News

Donor Management Boosted Heart Procurement

Author:
Neil Osterweil
Publish date: November 1, 2010

  • Read More

News

Assay Identifies Trauma Patients Unresponsive to Platelet Inhibition

Author:
Neil Osterweil
Publish date: October 22, 2010

Major Finding: More than two-thirds of trauma patients reporting use of clopidogrel were found to have subtherapeutic platelet inhibition.Data...

  • Read More

News

Assay Identifies Trauma Patients Unresponsive to Platelet Inhibition

Author:
Neil Osterweil
Publish date: October 22, 2010

Major Finding: More than two-thirds of trauma patients reporting use of clopidogrel were found to have subtherapeutic platelet inhibition.Data...

  • Read More

Pages

  • « first
  • …
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • last »

Privacy Policy

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2022 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close